Wells Fargo Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)
Balanced Outlook Amidst Strategic Shifts: Pfizer's Hold Rating Explained
Pfizer's Acoramidis Shows Promising Survival Trends: A Buy Rating Endorsement
Redburn Adjusts Price Target on Abbott Laboratories to $113 From $115
Goldman Sachs Adjusts Price Target on Eli Lilly to $785 From $740
Abbott Laboratories Analyst Ratings
Optimistic Buy Rating for Abbott Laboratories on Diverse Portfolio and Growth Prospects
Truist Financial Sticks to Its Buy Rating for Corcept Therapeutics (CORT)
Corcept Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT), Theravance Biopharma (TBPH) and Merus (MRUS)
Berenberg Bank Reaffirms Their Hold Rating on Pfizer (PFE)
Jefferies Adjusts Price Target on Eli Lilly to $925 From $915
Critical Insights From Abbott Laboratories Analyst Ratings: What You Need To Know
Abbott Laboratories Analyst Ratings
Johnson & Johnson Analyst Ratings
Citigroup Adjusts Price Target on Abbott Laboratories to $119 From $128, Keeps Buy Rating
Analysts Are Bullish on These Healthcare Stocks: AbbVie (ABBV), Aerovate Therapeutics (AVTE)
Wells Fargo Remains a Hold on Pfizer (PFE)
Barclays Sticks to Its Hold Rating for Amgen (AMGN)
Jefferies Raises Regeneron Pharmaceuticals' Price Target to $1,125 From $1,115